Physician profile
Bobby D Peterson
NPI 1841359171
$2,687.27
in general payments reported to CMS, 2019-2025
24 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $183 · 2021: $367 · 2022: $198 · 2023: $658 · 2024: $512 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $915.97 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $422.15 | 2019-2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $251.11 | 2021-2025 | |
| Lilly USA, LLC | $237.92 | 2022-2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $131.35 | 2019-2024 | Eliquis |
| Glaxosmithkline, LLC. | $129.34 | 2019-2020 | |
| Amgen INC. | $86.46 | 2022-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $68.26 | 2022-2023 | |
| Ultragenyx Pharmaceutical INC. | $56.30 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.42 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.99 | 2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $39.55 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $35.48 | 2022-2024 | Gardasil 9, Gardasil, Capvaxive |
| Esperion Therapeutics, INC. | $29.63 | 2021 | |
| Allergan, INC. | $28.65 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $27.66 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $27.17 | 2023 | Quviviq |
| Kyowa Kirin, INC. | $25.16 | 2023 | Crysvita |
| Dexcom, INC. | $21.08 | 2021 | |
| Abbvie INC. | $17.97 | 2024 | |
| Pfizer INC. | $15.68 | 2019 | |
| Sanofi Pasteur INC. | $13.44 | 2024 | |
| Amarin Pharma, INC. | $12.49 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.